Tag Archives: THR-β agonist

CureGene Ph1 THR-β Agonist Study; Compounded Reta Real World Study

Two cardiometabolic-related news items have been observed: CureGene Pharmaceutical dosed the first patient in its FIH THR-β agonist study (view press release; view CT.gov record), and a study was conducted comparing compounded retatrutide to non-compounded retatrutide, tirzepatide, and semaglutide (view article). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

JPM 2026 Day 2: LLY, NVO, AMGN, VKTX, AZN, MRK, IONS; Obesity Association Debuts Standards of Care for Obesity Medications

On the second day of JPM 2026, FENIX has provided coverage of presentations by major CVRM companies, including Lilly, Novo Nordisk, Amgen, Viking Therapeutics, AstraZeneca, Merck, and Ionis Pharmaceuticals. Separately, one CVRM-related news item has been observed: The Obesity Association published new standards of care for obesity medications (view press release). Below, FENIX provides insights and highlights for the guidelines.

This content is for Read Less members only.

Already a member? Log in here